The Cancer Research Institute (CRI) Technology Impact Award supports early-stage, high-risk, high-reward technological innovations that have the potential to transform cancer immunotherapy. The program funds the development of new tools, platforms, and systems to address critical barriers in understanding and treating cancer through the immune system.
Eligibility criteria:
-
Applicants must hold a tenure-track position at a nonprofit research institution.
-
Co-Principal Investigators (Co-PIs) are allowed and encouraged.
-
Open to technology developers and clinical cancer immunologists; collaborative proposals are welcomed.
-
Research must focus on innovation in technology development applicable to cancer immunotherapy.
Funding details:
-
Amount: up to 600,000 USD total over 2–4 years.
-
Supports early conceptual and pre-development work (not continuation of existing technologies).
-
Indirect costs: up to 10% (in addition to the total award).
-
Clinical trials not supported, but use of samples from existing trials is permitted.
Deadline:
-
Letter of Intent: November 15, 2025.
-
Invited full proposal: March 2, 2026.
-
Earliest award start date: July 1, 2026.
Where to go for further information:
- Program details available at cancerresearch.org.
- Contact: [email protected]